Jing-Yi Chung
Research Subjects
Jing-Yi Chung has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Marson
University of California, San Francisco 1 Department of Medicine San Francisco, California
1 shared publication - Alexis Talbot
University of California, San Francisco 1 Department of Medicine San Francisco, California
1 shared publication Allison G. Rothrock
1 shared publication- Angela To
Department of Psychiatry, Yale University School of Medicine, New Haven, USA
1 shared publication - Avishai Shemesh
Department of Medicine, University of California , San Francisco, CA
1 shared publication - Carl C. Ward
Gladstone–UCSF Institute of Genomic Immunology, San Francisco, USA
1 shared publication
Latest Publications
- Open Access
Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.
Open AccessSite-specific genome engineering of primary human natural killer cells for programmable anti-tumor function
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.